COMMENT: Alkermes Needs New Strategy In Wake Of Trial Failures
This article was originally published in Scrip
Executive Summary
Following the failure of two pivotal studies, Alkermes is unlikely to keep ALKS 5461 alive and must instead redefine its strategy, says Datamonitor Healthcare lead analyst Daniel Chancellor.